TC-011

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameTC-011
Drug Alias NameTC-011TC011
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTicaros Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTicaros Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A